{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T11:51:47Z","timestamp":1772711507007,"version":"3.50.1"},"reference-count":22,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T00:00:00Z","timestamp":1635033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Hepatic diseases are an important public health problem. All patients with chronic hepatitis C virus (HCV) infection receive treatment, regardless of hepatic fibrosis severity. However, evaluation of hepatic fibrosis and steatosis is still useful in assessing evolution, prognosis and monitoring of hepatic disease, especially after treatment with direct-acting antivirals (DAAs). The aim of this study was to assess the link between patatin-like phospholipase domain-containing 3 (PNPLA3) polymorphism and the degree of hepatic steatosis and fibrosis in patients with chronic HCV infection, as well as changes in steatosis and fibrosis three monthsafter obtaining a sustained viral response (SVR). Materials and Methods:Ourstudy included 100 patients with chronic hepatitis C (CHC) infection and compensated cirrhosis who received DAA treatment and who were evaluated using Fibromax prior to and 3 months after SVR. The influence of PNPLA3 (CC, CG, GG) genotype among these patients on the degree of post-treatment regression of steatosis and fibrosis was assessed. Results: Regression was noticed in the degree of both hepatic steatosis and hepatic fibrosis post-DAA treatment (three months after SVR). Analysis of the correlation between PNPLA3 genotype and fibrosis indicated that the average level of fibrosis (F) before DAA treatment was higher in patients with the GG genotype than in patients with the CC or CG genotype. Three months after SVR, the average level of fibrosis decreased; however, it remained significantly increased in GG subjects compared to that in CC or CG patients. The degree of hepatic steatosis before treatment was not significantly different among patients with different PNPLA3 genotypes, and no significant correlations were observed three months after SVR. Conclusions: The genetic variants of PNPLA3 influence the evolution of hepatic fibrosis. The GG subtype plays an important role in the degree of hepatic fibrosis both before and after treatment (three months after SVR)and could be a prognostic marker for assessment of post-SVR evolution.<\/jats:p>","DOI":"10.3390\/medicina57111153","type":"journal-article","created":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T22:07:11Z","timestamp":1635113231000},"page":"1153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response"],"prefix":"10.3390","volume":"57","author":[{"given":"Oana Irina","family":"Gavril","sequence":"first","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-7043","authenticated-orcid":false,"given":"Lidia Iuliana","family":"Arhire","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (II), Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otilia","family":"Gavrilescu","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Dranga","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oana","family":"Barboi","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radu Sebastian","family":"Gavril","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2183-0690","authenticated-orcid":false,"given":"Roxana","family":"Popescu","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Cijevschi Prelipcean","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9144-5520","authenticated-orcid":false,"given":"Anca-Victorita","family":"Trifan","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catalina","family":"Mihai","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties (I), Faculty of Medicine, \u201cGrigore T. Popa\u201d Universityof Medicine and Pharmacy, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.12998\/wjcc.v6.i13.589","article-title":"Update on global epidemiology of viral hepatitis and preventive strategies","volume":"6","author":"Meryem","year":"2018","journal-title":"World J. Clin. Cases"},{"key":"ref_2","first-page":"123","article-title":"Liver transplantation around the world","volume":"22","author":"Trotter","year":"2017","journal-title":"Liver Transpl."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2","DOI":"10.21037\/tgh.2019.09.06","article-title":"Genetic and epigenetic disease modifiers: Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD)","volume":"5","author":"Choudhary","year":"2021","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/hep.24123","article-title":"Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C","volume":"53","author":"Valenti","year":"2011","journal-title":"Hepatology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1002\/hep4.1228","article-title":"Morphometry Confirms Fibrosis Regression From Sustained Virologic Response to Direct-Acting Antivirals for Hepatitis C","volume":"21","author":"Pan","year":"2018","journal-title":"Hepatol. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s10620-019-05886-y","article-title":"Noninvasive Measurements Predict Liver Fibrosis Well in Hepatitis C Virus Patients After Direct-Acting Antiviral Therapy","volume":"65","author":"Huang","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jvh.13204","article-title":"Time-dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct-acting antiviral therapy of chronic hepatitis C","volume":"27","author":"Laursen","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.3748\/wjg.v25.i40.6094","article-title":"Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study","volume":"28","author":"Colussi","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/j.1572-0241.2002.06038.x","article-title":"Sampling error and intraobservervaria-tion in liver biopsy in patients with chronic HCV infection","volume":"97","author":"Regev","year":"2002","journal-title":"Am. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/hepr.12331","article-title":"Progressive fibrosis significantly correlates with hepatocellular carcinoma in patients with a sustained virological response","volume":"21","author":"Tachi","year":"2015","journal-title":"Hepatol. Res."},{"key":"ref_12","first-page":"39","article-title":"Changes in hepatic fibrosis stages after achieving SVR following direct-acting anti-viral treatment: A prospective stud","volume":"18","author":"Shina","year":"2020","journal-title":"GastroHep"},{"key":"ref_13","first-page":"2347","article-title":"Regression of liver fibrosis after curing chronic hepatitis C with oral antivirals in patients with and without HIV coinfection","volume":"23","author":"Carrasco","year":"2018","journal-title":"AIDS"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/MEG.0000000000000964","article-title":"Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: Results of hepatology clinic HEPA experience","volume":"29","author":"Dolmazashvili","year":"2017","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3748\/wjg.v24.i11.1269","article-title":"Fatty liver in hepatitis C patients post-sustained virological response with direct-acting antivirals","volume":"21","author":"Noureddin","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.23736\/S1120-4826.20.02619-1","article-title":"Molecular mechanisms of hepatic fibrosis in chronic liver diseases","volume":"32","author":"Rosso","year":"2020","journal-title":"Minerva Biotecnol"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jcv.2018.04.008","article-title":"PNPLA3 rs738409 polymorphism is associated with liver fibrosis progression in patients with chronic hepatitis C: A repeated measures study","volume":"103","author":"Resino","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Manchiero, C., Nunes, A.K.d., Magri, M.C., Dantas, B.P., Mazza, C.C., Barone, A.A., and Tengan, F.M. (2017). The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-017-2887-6"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"9521","DOI":"10.1073\/pnas.1901974116","article-title":"Accumulation of PNPLA3 on lipid droplets is the basis of associated hepatic steatosis","volume":"116","author":"BasuRay","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fmed.2019.00304","article-title":"PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease","volume":"17","author":"Dong","year":"2019","journal-title":"Front Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.aohep.2018.10.004","article-title":"Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population","volume":"18","author":"Mazo","year":"2019","journal-title":"Ann. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kawagishi, N., Suda, G., Nakamura, A., Kimura, M., Maehara, O., Suzuki, K., Nakamura, A., Ohara, M., Izumi, T., and Umemura, M. (2018). Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0209615"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/11\/1153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:13Z","timestamp":1760167333000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/57\/11\/1153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,24]]},"references-count":22,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["medicina57111153"],"URL":"https:\/\/doi.org\/10.3390\/medicina57111153","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,24]]}}}